Physical performance in older people: actual evidence by Bruyère, Olivier
tendinopathies remains scientifically controversial, particularly
due to the diversity of products that go by the name of ‘PRP.’
Recently, the viscoelastic properties of hyaluronic acid (HA)
on liquid connective tissue have been proposed for the treat-
ment of tendinopathies. Some fundamental studies show en-
couraging results on hyaluronic acid’s ability to promote ten-
don gliding and reduce adhesion as well as to improve tendon
architectural organisation. Some observations also support its
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The pleiotropic effects of vitamin D, specifically its extra-
skeletal effects, remains controversial, despite an abundance
of existing literature. Through biomarker discovery using 3D
LC-nESI-FTMS quantitative proteomics, we revealed the dif-
ferent signature proteins activated by vitamin D that is influ-
enced by sex and vitamin D status. The present study included
vitamin D deficient Saudi adults recruited from several cen-
ters. The first phase is the biomarker discovery phase through
profiling of pooled serum proteomes (males=31; females=28)
and identified 2472 reproducible proteins, among which 248
exhibited significant modulation between men and women
that mapped pathways associated with several key metabolic
pathways including vitamin D function.
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The present study is the vitamin D biomarker discovery using
the same depletion-free quantitative proteomics among vita-
min D deficient subjects (males=26; females=24) that
achieved vitamin D correction after 12-month vitamin D cor-
rection. The most significant biomarkers identified included
those from the coagulation pathway, lipids, apolipoproteins,
inflammatory markers, insulin growth factors and other pro-
teins. Differentially expressed proteins were subjected to in
silico bioinformatics assessment using principal component
analysis, hierarchical clustering andMetacore™ pathway anal-
ysis. These identified proteins were also sexually-dimorphic.
These sex-mediated effects should be factored in the design
and interpretation of vitamin D observational/interventional
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The biomarker validation phase involved 35 most significantly
modulated signature proteins using enzyme-linked immunosor-
bent assays from 259 vitamin D deficient participants stratified
according to response to 6-month vitamin D supplementation
[Responders: (25(OH)D >50nmol/l, N=162 (70 males; 92 fe-
males); Non-responders: 25(OH)D <50nmol/l, N=97 (27
males; 70 females)]. The last phase confirmed the associations
of the identified biomarkers only among thosewhose vitaminD
status responded to vitamin D status correction. Our series of
studies confirm the importance of vitamin D in human metab-
olism at the proteomic level and the significant expression of
major clinical biomarkers and their respective metabolic path-
ways depending on vitamin D supplementation response.
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The loss of muscle mass in older people is one of the key
mechanisms leading to sarcopenia. Therefore the evaluation
of muscle mass is of remarkable importance in the evaluation
of sarcopenic patient. In this presentation, we will discuss the
importance to assess muscle mass in older people. In particu-
lar, we will deal with the most relevant tools used for assessing
body composition in the diagnosis of sarcopenia including
DXA, BIA, magnetic resonance, echography and CT. A par-
ticular focus will be given to the pitfalls and the current issues
in assessing muscle mass in the elderly.
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Together with the evaluation of the muscle mass, phys-
ical performance assessment is of extreme importance in
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the diagnosis of sarcopenia in older people. Recent
guidelines of sarcopenia have modified the indications
for assessing physical performance and muscle strength
in older people. Moreover, some tests for evaluating
physical performance (such as gait speed, TUG, SPPB)
are of common use, whilst we have other new tests that
are less known, but that seem to have an important
prognostic value. In this presentation, we will discuss
the use of these tests, with a focus of their use in older
people and the actual issues and perspectives regarding
this topic.
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Sarcopenia is becoming a new geriatric giant due to its
high prevalence and to the negative outcomes associated
with this condition. In these years, sarcopenia was in-
troduced in the new classification of medical conditions,
i.e. in the ICD 10 classification. However, sarcopenia is
often assessed in academic centers, whilst its assessment in
usual care is still limited. In this presentation, we will sum-
marize the main findings of the two previous presentations
and we will discuss how to improve the diagnosis of
sarcopenia in older people, as standard evaluation, in daily
practice.
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The prevalence of osteoporosis is less than 2% in wom-
en younger than 50 years, while between the ages of 20
and 40 years, the prevalence is only 1.2%. Physiological
changes during puerperal-pregnancy cycle could lead to
a rare disease: the pregnancy- and lactation-associated
osteoporosis (PLO). This rare disorder could affect
young women during pregnancy, postpartum period, or
while breastfeeding.
During pregnancy, major modifications of the calcium
metabolism and bone mineral status of the mother occur,
in order to meet the needs of the fetus for optimal growth
of its skeleton and its mineralization. Fragility fractures
have been described, but this occurs infrequently. It is
possible that there is underdiagnosis as a result of the
overlapping symptomatology with the frequent aches af-
fecting normal pregnancies. Factors that may overlap ma-
ternal metabolic adaptations may have hormonal etiology,
nutritional deficiency, mechanical changes, pharmacolog-
ical association, renal disturbance, connective tissue dis-
orders, other non-specified genetic disorders and idio-
pathic osteoporosis. Perhaps identification of this at-risk
group may lead to effective interventions to reduce bone
fracture risk in later life.
There are no established diagnostic criteria for PLO. However,
a diagnosis can be easily obtained by an accurate medical
interview, physical examination, imaging studies, and labora-
tory data, including bone mineral density measurement after
delivery. This disease should be suspected when a woman
presents with severe back pain in the late stages of pregnancy
or the early postpartum period. An accurate and prompt diag-
nosis helps with appropriate treatment and prevents the pro-
gression of the disease.
There are no solid clinical practice guidelines for the man-
agement of this condition and treatment strategy remains
controversial. Clinical judgment must be used to balance
the potential benefit and risks of treatment that is being
considered. The suggested treatment strategy includes op-
timize calcium and vitamin D intake, load reduction and
analgesia. Cessation of lactation seems to be the major
classical treatment in the reports. There is much uncertain-
ty about whether pharmacological bone-specific therapy
should be used for osteoporosis that presents during preg-
nancy or lactation. The temptation to prescribe anti-
osteoporosis medications for pregnancy or lactation-
induced osteoporosis needs to be tempered with the real-
ization that BMD normally increases during the 6 to 12
months after weaning, with apparent recovery of the prior
level of BMD and bone strength. Given the concerns
about long-term safety, clinicians should carefully consid-
er whether to commit a young woman to long-term treat-
ment with these agents, especially since there is no clearly
defined endpoint for treatment.
For avoiding post-pregnant osteoporosis and decrease in
bone mass during pregnancy or lactation period, it is
necessary to obtain sufficient bone mass before, during
the growth period and maintain bone mass in adulthood.
In addition to the prevention of post-pregnant osteopo-
rosis, to avoid future osteoporosis and fragility fractures
of older age, it is necessary to promote young women
to take measures such as adequate nutrition intake and
exercise habits, considering bone health.
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